BMY Financial Facts
Net Earnings Attributable to Noncontrolling Interest: 13MNet Sales: 4.92B
See Full Income Statement
Marketable securities: 3.04B
Commitments and contingencies (Note 14): 0
See Full Balance Sheet
Bristol-Myers Squibb Company (BMY) Earnings
|
Expand Research on BMY
| Next EPS Date | 7/31/26 *Est. | EPS Growth Rate | -100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +19.0% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | +3.5% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
4/30/26  |
Q126 | N/A | $1.45 | N/A | N/A | $10.84B | = | N/A | N/A | ||
| 2/5/26 | Q425 | $1.26 | $1.12 | +$0.14 | $12.5B | $12.24B | = |  | | Details | |
| 10/30/25 | Q325 | $1.63 | $1.52 | +$0.11 | $12.2B | $11.8B | = | | | Details | |
| 7/31/25 | Q225 | $1.46 | $1.06 | +$0.40 | $12.27B | $11.34B | = | | | Details | |
| 4/24/25 | Q125 | $1.80 | $1.52 | +$0.28 | $11.2B | $10.68B | = | | | Details | |
| 2/6/25 | Q424 | $1.67 | $1.47 | +$0.20 | $12.34B | $11.54B | = | | | Details | |
| 10/31/24 | Q324 | $1.80 | $1.50 | +$0.30 | $11.9B | $11.26B | = | | | Details | |
| 7/26/24 | Q224 | $2.07 | $1.64 | +$0.43 | $12.2B | $11.52B | = | | | Details |
